【恒瑞医药：子公司收到HRS9531注射液临床试验批准通知书】金十数据5月30日讯，恒瑞医药公告称，子公司福建盛迪医药有限公司收到国家药监局核准签发关于HRS9531注射液的《药物临床试验批准通知书》，将于近期开展临床试验。目前全球范围内，仅有礼来的同靶点药物替尔泊肽注射液于2022年在美国获批上市，用于治疗2型糖尿病。HRS9531相关项目累计研发投入约3.45亿元。根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通知书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.